Company news

Compass Therapeutics, Inc. (NASDAQ:CMPX) news

Compass Therapeutics, Inc. news releases on 6ix. Latest, Sep 22, 2026: Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer…

Compass Therapeutics, Inc. (NASDAQ:CMPX) news

Press releases & updates

Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

Compass Therapeutics to Participate in Upcoming June Investor Events

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting

Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer

Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update

Compass Therapeutics Provides Corporate Update

Compass Therapeutics Announces Key Leadership Appointments

Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference

Compass Therapeutics to Participate in Upcoming December Investor Events

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Compass Therapeutics to Participate in Upcoming November Investor Events

Compass Therapeutics to Participate in Upcoming September Investor Events

Compass Therapeutics Announces Proposed Public Offering

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

Compass Therapeutics to Participate in Upcoming May Investor Events

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Compass Therapeutics to Participate in Upcoming Investor Events

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update

Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference

Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer

Compass Therapeutics Announces CEO Transition

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual...

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated

Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days